Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91
Benzinga Newsdesk 3 months ago
NewsInitiationAnalyst RatingsPrice Target
Canaccord Genuity analyst Gary Nachman initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold rating and announces Price Target of $91.
Canaccord Genuity analyst Gary Nachman initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold rating and announces Price Target of $91.